Oral Aleniglipron Reduced Weight at 36 Weeks - Summary - MDSpire

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

Objective:

To evaluate the efficacy of once-daily aleniglipron in reducing body weight in adults with obesity or overweight without diabetes.

Approach:
  • Trial Design: A randomized phase 2b double-blind, placebo-controlled trial (ACCESS) conducted at 38 US sites.
  • Participants: 406 adults screened; 230 randomly assigned to aleniglipron (45 mg, 90 mg, 120 mg) or placebo.
  • Endpoints: Primary endpoint was percentage change in body weight from baseline to week 36.
Key Findings:
  • Atwek36simdnboyghcl945102prju8fv
Interpretation:

The study demonstrated significant weight loss with aleniglipron compared to placebo, with a favorable safety profile despite common gastrointestinal side effects.

Limitations:
  • EnrolmtxcusivyadpWhgzbf
Conclusion:

Aleniglipron was associated with significant weight loss in adults with obesity or overweight without diabetes.

Sources:

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

FDA Names PreCheck Participants

Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.

New CDC Report Tracks US Mortality Trends

The annual provisional report summarizes changes in mortality rates, demographic patterns, and leading causes of death during 2025.

FDA Approves Dual-Energy Catheter Ablation Platform

The platform integrates with the CARTO ecosystem and enables physicians to use either pulsed field or radiofrequency energy based on patient anatomy and case complexity.